摘要
目的探讨莫沙必利联合雷贝拉唑在胃食管反流中的应用效果。方法选择2019年2月—2020年1月该院收治的102例胃食管反流患者作为研究对象,以随机数表法将其分为两组,其中对照组与研究组各51例。对照组口服雷贝拉唑治疗,研究组在此基础上联合莫沙必利治疗。对比两组患者的临床疗效、治疗前后血清一氧化氮(NO)水平,以及药物不良反应。结果研究组治疗的总有效率为96.08%,高于对照组80.39%,差异有统计学意义(χ^(2)=6.044,P<0.05)。治疗后研究组血清NO水平(78.5±5.6)μmol/L低于对照组(89.5±5.0)μmol/L,差异有统计学意义(t=10.464,P<0.05)。研究组治疗期间不良反应发生率为5.88%,与对照组7.84%对比差异无统计学意义(χ^(2)=0.000,P>0.05)。结论莫沙必利联合雷贝拉唑在胃食管反流中具有显著的应用效果。
Objective To explore the effect of mosapride combined with rabeprazole in gastroesophageal reflux.Methods 102 cases of gastroesophageal reflux patients admitted to the hospital from February 2019 to January 2020 were selected as the research objects,and they were divided into two groups by random number table method,including 51 cases in the control group and 51 cases in the study group.The control group was treated with rabeprazole orally,and the study group was treated with mosapride on this basis.The clinical efficacy,serum nitric oxide(NO)levels before and after treatment,and adverse drug reactions were compared between the two groups of patients.Results The total effective rate of treatment in the study group was 96.08%higher than that of the control group 80.39%,the difference was statistically significant(χ^(2)=6.044,P<0.05).After treatment,the serum NO level(78.5±5.6)μmol/L of the study group was lower than that of the control group(89.5±5.0)μmol/L,the difference was statistically significant(t=10.464,P<0.05).The incidence of adverse reactions during treatment in the study group was 5.88%,which was not statistically different from 7.84%in the control group(χ^(2)=0.000,P>0.05).Conclusion Mosapride combined with rabeprazole has a significant application effect in gastroesophageal reflux,
作者
易胜冬
李莉
YI Sheng-dong;LI Li(Department of General Internal Medicine,Shanghe County People's Hospital,Shanghe,Shandong Province,251600 China)
出处
《世界复合医学》
2021年第1期178-180,共3页
World Journal of Complex Medicine
关键词
莫沙必利
雷贝拉唑
胃食管反流
Mosapride
Rabeprazole
Gastroesophageal reflux
